Facebook Instagram X-twitter Linkedin

Tesamorelin (20mg)

Table of Contents

  • Quickstart Highlights

Tesamorelin (20mg) protocols focus on this synthetic growth hormone-releasing hormone (GHRH) analog designed to stimulate endogenous growth hormone secretion. It is primarily studied for its ability to increase IGF-1 levels and may support reductions in visceral adipose tissue, improved body composition, and metabolic regulation. This guide outlines a subcutaneous administration approach optimized for the 20 mg vial format.

  • Reconstitute: Add 2.0 mL bacteriostatic water → 10 mg/mL concentration
  • Typical daily range: 1–2 mg per day (subcutaneous, clinical/research settings)
  • Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U-100 insulin syringe
  • Storage: Lyophilized: store at −20 °C; after reconstitution, refrigerate at 2–8 °C and use within 21–28 days
  • Protocol Overview

Concise summary of the subcutaneous regimen.

  • Goal: Support reduction of visceral fat and improve body composition via GH/IGF-1 axis stimulation
  • Schedule: Daily subcutaneous injections
  • Dose Range: 1–2 mg per day (commonly used in research and clinical contexts)
  • Dosing Protocol

Suggested approach for the 20 mg vial format.

  • Start: 0.5–1 mg daily to assess tolerance
  • Target: 1–2 mg once daily (subcutaneous)
  • Frequency: Once daily, preferably at the same time each day
  • Vial Duration: One 20 mg vial lasts approximately 10–20 days, depending on dosing
  • Timing: Typically administered in the evening or before bed to align with the natural GH rhythm
  • Mechanism of Action

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds to pituitary GHRH receptors, stimulating the natural pulsatile release of growth hormone. This increase in growth hormone subsequently elevates insulin-like growth factor 1 (IGF-1) production in the liver.

Through activation of the GH/IGF-1 axis, tesamorelin may promote lipolysis, particularly in visceral (abdominal) fat deposits, while supporting protein synthesis and metabolic regulation. Clinically, it has been studied for its effects on reducing excess abdominal fat in specific patient populations, with measurable improvements in body composition.

  • Potential Benefits & Side Effects

Observations based on clinical research and approved medical use in specific indications.

Potential Benefits:

  • May reduce visceral (abdominal) fat accumulation
  • May improve body composition and metabolic markers
  • May increase IGF-1 levels and support GH signaling
  • May support lipid profile improvements in some studies

Possible Side Effects:

  • Injection-site reactions
  • Joint pain or stiffness
  • Water retention
  • Possible increase in blood glucose levels
  • Headache or flushing in some cases
  • Should be used under medical supervision; not intended for unsupervised use